logo
Plus   Neg
Share
Email

Ingenico Q4 Revenue Up 13% - Quick Facts

Ingenico (INGIF.PK) Wednesday said its fourth quarter revenue was €353 million, up 13 percent on a reported basis and 10 percent on a comparable basis.

The company said this included a positive foreign exchange impact of €5 million. Total revenue included €294 million generated by the Payment Terminal activity and €59 million generated by Transaction Services.

In 2012, the net profit attributable to Ingenico S.A. shareholders was €97 million, up 71% from €56 million in 2011. In 2012, net earnings per share were €1.87, up from €1.11 in 2011.

Revenue for full year 2012 was €1.206 billion, up 20 percent on a reported basis and 14 percent on a comparable basis.

EBITDA increased by 21 percent to €223 million, up from €184 million in 2011. The EBITDA margin increased by 50 basis points to 18.5 percent of revenue, as against restated pro forma 2011.

Ingenico expects to post a revenue growth greater or equal than 8% on a comparable basis and an EBITDA1 margin growth of 18.5% or higher.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT